In the 3Q ended Sept 30, 2019, Duopharma Biotech's net profit increased by 20.9% to RM14.86mil from RM12.28mil a year ago.
KUALA LUMPUR: Duopharma Biotech Bhd
, which recorded stronger earnings in the third quarter ended Sept 30,2019, will push ahead with its foray into the specialty products as one of its strategies to create a pool of niche products.
It said on Friday it had recently obtained registration approval and launched Erysaa, an Erythropoeitin (EPO) product. EPO is the protein present in the human body that adjusts the red blood cell (RBC) generation in accordance with the oxygen requirement of the human body.
Already a subscriber? Log in.
Limited time offer:
Just RM5 per month.
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!
